Correspondence 0001213900-24-011800 from Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: Feb. 9, 2024 · CIK: 0001611747 · Accession: 0001213900-24-011800
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276767
Letter
Scinai Immunotherapeutics Ltd.
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
February 9, 2024
Via EDGAR Transmission
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Scinai Immunotherapeutics Ltd.
Registration Statement on Form F-3
Filed January 30, 2024
Registration No. 333-276767
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on February 13, 2024 at 9:15 a.m. Eastern Time or as soon thereafter as practicable, or at such later time as Scinai Immunotherapeutics Ltd. (the “Company”) or its counsel may request via telephone call to the staff.
Please contact Steven A. Lipstein of Lucosky Brookman LLP, counsel to the Company, at (732) 395-4416, or in his absence, Perry Wildes of Goldfarb Gross Seligman & Co., counsel to the Company, at + 972-3-607-4444, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Scinai Immunotherapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Scinai
Immunotherapeutics Ltd.
Jerusalem
BioPark, 2nd Floor
Hadassah
Ein Kerem Campus
Jerusalem,
Israel
February
9, 2024
Via
EDGAR Transmission
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
Scinai Immunotherapeutics Ltd.
Registration Statement on Form F-3
Filed January 30, 2024
Registration No. 333-276767
Ladies
and Gentlemen:
In
accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby
request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on February
13, 2024 at 9:15 a.m. Eastern Time or as soon thereafter as practicable, or at such later time as Scinai Immunotherapeutics Ltd. (the
“Company”) or its counsel may request via telephone call to the staff.
Please
contact Steven A. Lipstein of Lucosky Brookman LLP, counsel to the Company, at (732) 395-4416, or in his absence, Perry Wildes of Goldfarb
Gross Seligman & Co., counsel to the Company, at + 972-3-607-4444, to provide notice of effectiveness, or if you have any other questions
or concerns regarding this matter.
Sincerely yours,
Scinai Immunotherapeutics Ltd.
By:
/s/ Amir
Reichman
Amir Reichman
Chief Executive Officer
cc:
Steven A. Lipstein, Lucosky Brookman LLP
Perry Wildes, Goldfarb Gross Seligman & Co.